Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$41.09M$41.09M+2,672.3% vs Q3 2021 Net Income$17.62M$17.62MN/M vs Q3 2021 EPS Diluted$0.45$0.45N/M vs Q3 2021 Operating Income$14,442,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$16,484,000N/M Margins · derivedOperating margin35.2%+1731.9 pt vs Q3 2021
Net margin42.9%+1739.0 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end